NCT02530060View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Healthy

Interventions

DRUG

Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC

Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).

Trial Locations (1)

Unknown

Fukuoka